After years of demands from shareholders for another major deal, Gilead has made a spectacular move, sealing a deal to acquire cell therapy leader Kite for just under $12 billion. Gilead had been ...

Gilead has completed its $11.9 billion landmark acquisition of Kite Pharma, as the pharma switches focus from hepatitis C to cancer and revolutionary CAR-T therapies. The California-based pharma ...

Gilead is spending $12 billion to buy Kite Pharma, a biotech that has no approved therapies yet. The drugmaker's therapy that's a few months away from a possible approval is a highly personalized ...